Sanofi Announces Resignation of Global Head of R&D John Reed, MD

On February 13, Sanofi announced that Dr. John Reed, the company's global head of R&D, will resign to pursue new opportunities. Sanofi has begun searching for a successor from internal or external candidates. Dr. Dietmar Berger has agreed to temporarily take over the team. Since joining Sanofi in 2019, Dr. Berger has served as Chief Medical Officer and Global Head of Development. He has held positions at several pharmaceutical companies, including Genentech, Bayer, and Amgen, accumulating extensive and successful industry experience.

Since joining Sanofi in 2018, John has laid the foundation for the company's R&D transformation. He has helped reposition the discovery and development of new therapies at Sanofi, focusing on first-in-class and best-in-class drugs that have the potential to change medical practice and improve the lives of patients with serious diseases. At the same time, he has integrated and developed new technology platforms and partnerships, thereby enhancing R&D efficiency.

Dr. John Reed (Source: Sanofi Official Website)

John once served as the Global Head of Roche's Pharmaceutical Research and Early Development. Before joining Roche, he was the CEO of a large, independent, nonprofit biomedical research institution, with an outstanding track record.

In 2023, Sanofi is set to launch two potential first and best in class drugs, addressing the primary needs of patients with hemophilia and respiratory syncytial virus, respectively. The company anticipates releasing 27 scientific data updates within the next 15 months, along with key clinical study data this year for multiple sclerosis and chronic obstructive pulmonary disease/chronic bronchitis.

Copyright © 2023 PHARMCUBE. All Rights Reserved.

Welcome to forward, share, and reasonably cite. When citing, please clearly indicate the source of the article; if you need to reproduce it, please leave a message or send a notification to the WeChat Official Account backend, and include the name and ID of the official account.

Disclaimer: The information in this WeChat article is for general reference only and should not be directly used as decision-making content. PharmaCube assumes no responsibility for any loss incurred by any party due to the use of the content herein.

Wonderful Live Broadcast

CUBE LIVE